Introduction
============

Adenoviruses are a class of double-stranded DNA viruses infecting the respiratory tract, eyes, intestines, urinary tract, and nervous system ([@B38]). HAdV type 55 (HAdV-55) causes severe pneumonia in immunocompetent people. HAdV-55 has a recombinant genome from HAdV-B11 which is a renal pathogen with the antigenic epitope, and HAdV-B14 which is a respiratory pathogen conferring the cell tropism, biological and pathological properties ([@B61]). From 2004 to 2006, three major outbreaks of HAdV-55 infection took place in Turkey, Singapore, and China mainland, eliciting nearly 1000 patients and 2 deaths ([@B54]). Other recent outbreaks are also reported ([@B29]; [@B68]).

Since the discovery of HAdV-55, several laboratory investigations have addressed the viral biology such as its genome and clinical manifestations after infection. Persistent high fever, cough and rapid progression of dyspnea were typically reported in the patients infected by HAdV-55 ([@B55]). However, the mechanisms of the initiation and progression of severe pneumonia remain ambiguous. It has been reported that serum cytokines such as IL-4 and IL-15 were significantly elevated in patients with severe infection ([@B11]). Another study demonstrates that patients with severe HAdV-55 infections showed significantly higher levels of blood IL-17^+^ CD4^+^ T lymphocytes and higher levels of serum IFN-γ, IFN-α2, IL-4, and IL-10 ([@B11]). These data suggest that excessive immune reactions or inflammatory responses might induce severe tissue damage in HAdV-55-infected patients. It has been well known that HAdVs stimulate a robust innate immune response, resulting from a wide array of viral effects on cellular pathways ([@B31]; [@B15]). Indeed, the viral genome triggers the formation of NLRP3 inflammasome via the stimulation of Toll-like receptor signaling, causing the activation of pro-inflammatory defense mechanism ([@B4],[@B5]; [@B53]). Thus, a thorough understanding of the inflammatory responses in HAdV-55 infection is important for developing efficacious therapies.

In recent years, transcriptome sequencing has become increasingly popular in new gene/mutation discovery and gene expression profiling. With this technology, a massive change in regulation of liver transcripts with robust up-regulation of immune-related genes was found in HAdV-5 infection in a rodent model ([@B63]). However, to our knowledge, no special elaboration was conducted to discover inflammation-related genes in HAdV-55 infection using a transcriptome analysis. Therefore, our study aimed to identify novel candidate genes which are substantially involved in the pathogenesis of severe inflammation in HAdV-55-infected patients. To achieve this goal, the transcriptome of peripheral blood mononuclear cells (PBMCs) in HAdV-55-infected patients was sequenced, *de novo* assembled, and used to compare the transcriptome profiles of patients with healthy volunteers. We found that the expression of eight genes, including *Il18*, *Il36b*, *Il17rc*, *Tnfsf10*, *Tnfsf11*, *Tnfsf14*, *Tnfsf15*, and *Il1a*, were closely correlated with the severity of HAdV-55 infection. Most of these genes belong to interleukin-1 family or tumor necrosis factor (TNF) superfamily, respectively. The changes in the expression of TNFSF10, 11, 14, and 15 were further confirmed by Western blot assay. Our data will deepen the comprehension of the pathogenic mechanisms of severe pneumonia post HAdV-55 infection.

Materials and Methods {#s1}
=====================

Patient Samples
---------------

Seventeen newly diagnosed patients with HAdV-55 infection, including six with pneumonia (group name "Severe"), six with upper-respiratory tract infection symptoms but without pneumonia (group name "Minor"), and five without any symptoms but having high anti-HAdV-55 IgM (group name "Silent"), were recruited from two outbreaks of HAdV-55 infection in 2011--2012 at two military camps. Informed consent was acquired from all patients. The experimental protocols were approved by the ethical committee of 302 Military Hospital of China (license number 2011033D) and conducted in compliance with corresponding regulations and guidelines. Peripheral venous blood was collected from these patients into EDTA-coated collection tubes. The blood mononuclear cells were isolated through the density gradient enrichment using Ficoll-Paque (GE Healthcare) according to the vendor's manual. The PBMCs were stored at -80°C before further analysis. Blood samples from six age-matched volunteers (health control, HC) were processed in the same way.

RNA Purification and cDNA Library Preparation
---------------------------------------------

Total RNA was purified from PBMCs using the phenol/chloroform method ([@B58]). RNase-free DNase I was used to remove residual genomic DNA contamination. RNA purity was checked using the kaiaoK5500^®^ Spectrophotometer (Kaiao, Beijing, China). RNA integrity and concentration were assessed with the RNA Nano 6000 Assay Kit of the Bioanalyzer 2100 system (Agilent Technologies, CA, United States). Only the samples with RNA quantity \>2 μg, RNA concentration \>200 ng/μl, RNA integrity value \>7 were used for transcriptome sequencing. Two microliters RNA per sample was used for the cDNA sample preparations using NEBNext^®^ Ultra^TM^ RNA Library Prep Kit for Illumina^®^ (\#E7530L, NEB, United States) following the manufacturer's recommendations and index codes were added to attribute sequences to each sample. Briefly, mRNA was purified from total RNA using poly-T oligo-attached magnetic beads. Fragmentation was carried out using divalent cations under elevated temperature in NEBNext First-strand Synthesis Reaction Buffer (5×). First strand cDNA was synthesized using random hexamer primer and RNase H. Second strand cDNA synthesis was subsequently performed using the buffer, dNTPs, DNA polymerase I and RNase H. The library fragments were purified with QiaQuick PCR kits and eluted with EB buffer. PCR was then performed to establish the library.

Library Examination
-------------------

Insert size was assessed using the Agilent Bioanalyzer 2100 system (Agilent Technologies, CA, United States), and qualified insert size was accurately quantified using StepOnePlus^TM^ Real-Time PCR System (Library valid concentration \>10 nM).

Library Clustering and Data Filtering
-------------------------------------

The clustering of the index-coded samples was performed on a cBot cluster generation system using HiSeq PE Cluster Kit v4-cBot-HS (Illumina) according to the manufacturer's instructions. Reads containing the sequence of adaptors (Adapter Polluted Reads), high content of unknown bases (Ns reads) and low-quality reads were removed from the raw data before further analysis to minimize data noise. In brief, the quality of the transcriptome libraries was first evaluated with FastQC v0.11.5. After that, the reads were assessed by standard quality control criteria, and the following reads were removed: (a) reads which were aligned to primers or adaptors, (b) reads with over 15% of low-quality bases (Q ≤19) in one read, (c) reads with over 5% unknown bases (N bases). After filtering, the remaining clean reads were stored in FASTQ format for further mapping ([Table 1](#T1){ref-type="table"}).

###### 

Sequencing data for each sample.

  Samples                         Silent       Minor        HC           Severe
  ------------------------------- ------------ ------------ ------------ ------------
  Raw reads number                54,366,912   66,856,104   53,894,280   55,572,122
  Adapter polluted reads number   1,532,952    2,163,132    5,176,046    1,198,878
  Ns reads number                 8,880        10,162       2,734        8,252
  Low-quality reads number        12,617,778   24,195,916   2,526,008    13,489,608
  Clean reads number              40,207,302   40,486,894   46,189,490   40,875,384
  Clean reads rate (%)^∗^         73.96        60.56        85.7         73.55
                                                                         

∗

Clean data rate (%), clean reads number/raw reads number. This is a representative table of two independent experiments.

Data Mapping and Gene Expression Analysis
-----------------------------------------

The clean reads of each group were aligned to the Human Genome version 19 (downloaded from ENSEMBL database^[1](#fn01){ref-type="fn"}^) using the software TopHat 2.0.12 plus Bowtie2 with the default parameter settings. Stringent quality control including sequencing data saturation analysis and reads distribution was performed for each sample to ensure the qualification of the sequencing data. Gene expression level was quantified via calculating Fragments per Kilobase per Millon Mapped Fragments (FPKM) as described in previous studies ([@B52]; [@B26]; [@B41]). The differential gene expression analysis was conducted using DESeq 1.18.0. The difference in gene expression between two groups was considered significant when the Log2 ratio ≥1 and *q*-value \<0.05. The details of gene mapping and expression analysis are introduced in [Supplementary Methods](#SM1){ref-type="supplementary-material"}.

Gene Annotation
---------------

To comprehensively investigate the potential roles of indicated differentially expressed genes (DEGs), GO enrichment analysis of DEGs were conducted by Hypergeometric test. The details of *GO Enrichment Analysis of DEGs* are depicted in [Supplementary Methods](#SM1){ref-type="supplementary-material"}.

Reverse Transcription and Quantitative Polymerase Chain Reaction (RT-qPCR)
--------------------------------------------------------------------------

The RNA extraction was performed as described above. Reverse transcription was conducted using All-In-One RT MasterMix (Applied Biological Materials Inc.). The following primers were used for quantifying corresponding gene expression: *Tnfsf14*: 5′-acaccactgcactccaacct-3′ and 5′-tgtcccccaagatctgtttc-3′; *Tnfsf11*: 5′-cccaacggtacacgactca-3′ and 5′-cgctagatgacaccctctcc-3′; *Il18*: 5′-tcaccagaggtcaggtgttc-3′ and 5′-ggctcaccacaacctctacc-3′; *Il36b*: 5′-ttttcctagcctcctcacca-3′and 5′-atttccactcaggacccaca-3′; *Tnfsf15*: 5′-gcagacggagataagccaag-3′ and 5′-gactctgggatcagcaggaa-3′; *Il-1a*: 5′-attcaccctggagcacaatc-3′ and 5′-aggggctagatttggagagg-3′; *Il-17rc*: 5′-agctgactcaggggtggag-3′ and 5′-agcccacagactgaccaaac-3′; *Tnfsf10*: 5′-gctgcctggctgacttaca-3′and 5′-aagcaatgccacttttggag-3′. The reaction was performed using Power SYBR^®^ Green Master Mix (Thermo Fisher Scientific) on a CFX384 Touch^TM^ Real-Time PCR Detection System (Bio-Rad, CA, United States) under the following condition: pre-denaturation at 95°C for 10 min, 40 cycles of denaturation at 95°C for 15 s and annealing at 63°C for 30 s. The expression of each gene was normalized to β-actin expression and calculated using the 2^-ΔΔCt^ method.

Immunoblotting
--------------

The proteins were isolated from PBMCs using the Total Protein Isolation Kit-Blood (ITSI-Biosciences, Johnstown, PA, United States) following the vendor's manual. Protein quantification was conducted using Quick Start^TM^ Bradford protein assay kit (Bio-Rad, CA, United States). A total of 60 μg of proteins from each sample were loaded onto 12% SDS-PAGE gels for electrophoresis. After that, the proteins were transferred onto PVDF membranes in Tris-Glycine transfer buffer at 100 volts at 4°C for 2 h, followed by blocking the membranes for 1 h with TBS-T buffer containing 5% fat-free milk. After three TBST-T washes, the membranes were incubated at 4°C overnight with 5 μg/ml of each of the following antibodies (all from Abcam, Cambridge, United Kingdom): anti-TRAIL (1:2000, Abcam ab42121), anti-RANKL (1:3000, Abcam ab9957), anti-TNFSF14 (1:1000, Abcam ab201094), anti-VEGI (1:1000, Abcam ab64986), and anti-GAPDH (1:2000, Abcam ab8245). The membranes were then washed with TBS-T and incubated with goat anti-mouse IgG or goat anti-rabbit IgG (1:5000. Both from Thermo Fisher Scientific, MA, United States) for 1 h at room temperature. After three washes with TBS-T, the membranes were developed using SuperSignal^®^ West Dura Extended Duration Substrate (Thermo Fisher Scientific, MA, United States), and the chemiluminescence was recorded and scanned using the ChemiDoc XRS+ system (Bio-Rad, CA, United States).

Statistics
----------

Data were presented as mean ± standard deviation. Unpaired *t*-test or one-way ANOVA was conducted for comparison of mean values among groups. Each experiment was independently repeated three or four times. *N* = 4 to 6 per group. The difference with a *p*-value \<0.05 was considered statistically significant.

Results
=======

RNA Expression Profiles in HAdV-55-Infected Patients
----------------------------------------------------

We carried out whole transcriptome analysis on mRNAs to study the changes in the cell transcriptome profiles of patients with different severity of HAdV-55-infection. One mRNA sample was randomly selected from each group for this analysis. The transcriptomes from patients and healthy donors were sequenced. The low-quality reads, Ns reads and adapter polluted reads were discarded and clean reads were used for mapping ([Table 1](#T1){ref-type="table"}). After mapping with TopHat 2.0.12 plus Bowtie2, the unmapped reads and multi-mapped reads were excluded, while the uniquely mapped reads were used for expression analysis.

Before the comparison between patients and healthy donors, mRNAs from two different healthy donors were sequenced and the result suggested that donor-donor variation was not significant (data not shown). In the following gene expression analysis, we mainly focused on the genes of which the expression was up-regulated. As shown in [Table 2](#T2){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}, in comparison with the healthy donor, 26,235 mRNAs were upregulated in the "Silent" patient ([Figure 1A](#F1){ref-type="fig"}), 30,235 mRNAs were upregulated in the "Minor" patient ([Figure 1B](#F1){ref-type="fig"}), and 24,831 mRNAs were upregulated in the "Severe" patient ([Figure 1C](#F1){ref-type="fig"}). Only a few mRNAs were down-regulated in each patient. Moreover, as compared with "Silent" patient, 11,766 mRNAs were up-regulated in the "Minor" patient ([Figure 1D](#F1){ref-type="fig"}), while 7247 mRNAs were up-regulated in the "Severe" patient ([Figure 1F](#F1){ref-type="fig"}). The "Severe" patient had 5910 up-regulated mRNAs as compared with the "Minor" patient ([Figure 1E](#F1){ref-type="fig"}). Our data suggest that HAdV-55-infection induced remarkable changes in gene expression in patients' PBMCs, and the severity of infection also influenced the PBMC gene expression.

###### 

Differentially expressed genes in different comparisons.

              Silent vs. HC   Minor vs. HC   Severe vs. HC   Minor vs. Silent   Severe vs. Silent   Severe vs. Minor
  ----------- --------------- -------------- --------------- ------------------ ------------------- ------------------
  **Up**      26,235          30,235         24,831          11,766             7,247               5,910
  **Down**    37              55             76              7,328              7,974               9,986
  **Total**   26,272          30,290         24,907          19,094             15,221              15,896
                                                                                                    

Up, up-regulation; Down, down-regulation.

![Volcano plot of gene expression changes. The transcriptomes of PBMCs from HAdV-55-infected patients and healthy controls were compared to each other (**A**--**F**, the comparison pairs were noted as the caption of every single volcano plot). The *x*-axis indicates the fold-changes. The *y*-axis displays the negative logarithm to the base 300 of the *t*-test *p*-values. Orange and green dots represent probe sets for transcripts expressed at significantly higher or lower levels in each comparison. HC: healthy control. Silent: patient without any symptoms. Minor: patient with respiratory tract infection symptoms but without pneumonia. Severe: patient with pneumonia.](fmicb-10-00130-g001){#F1}

GO Enrichment of Up-Regulated Genes in Infection
------------------------------------------------

To understand the functions of the up-regulated genes in patients, GO analysis of the up-regulated mRNAs in patients was performed. As shown in [Figure 2A](#F2){ref-type="fig"}--[C](#F2){ref-type="fig"}, with regard to the mRNAs that were upregulated in the "Silent," "Minor," and "Severe" patients relative to the healthy control, the GO enrichment showed highly similar patterns. The up-regulated mRNAs were mainly enriched in the biological process of "biological regulation," "single-organism process," and "metabolic process." In addition, several genes were enriched in inflammation-related process, such as "response to stimulus" and "immune system process." Notably, "response to stimulus" and "immune system process" were also enriched in the biological process in the DEGs of the "Minor" vs. "Silent" comparison ([Figure 2D](#F2){ref-type="fig"}), "Severe" vs. "Minor" comparison ([Figure 2E](#F2){ref-type="fig"}), as well as "Severe" vs. "Silent" comparison ([Figure 2F](#F2){ref-type="fig"}). Therefore, several inflammation-related genes were significantly up-regulated not only in HAdV-55-infection, but also were associated with the severity of the infection.

![GO enrichment of the up-regulated genes in each comparison (**(A--F)**, the comparison pairs were noted as the caption of every single plot). HC: healthy control. Silent: patient without any symptoms. Minor: patient with respiratory tract infection symptoms but without pneumonia. Severe: patient with pneumonia.](fmicb-10-00130-g002){#F2}

RT-qPCR Validation
------------------

To identify the genes that were involved in the inflammatory response after HAdV-55 infection, we focused on the DEGs enriched in "response to stimulus" and "immune system process" in each comparison and checked their fold changes. The up-regulated DEGs with a Log2 ratio ≥1 were first selected in each comparison, and the DEGs encoding inflammatory cytokines or cytokine-associated signaling molecules were further identified from the selected genes. Finally, we figured out several DEGs that were commonly up-regulated in all comparisons, and selected eight most up-regulated DEGs for further investigation, including *Il1a*, *Il18*, *Il36b*, *IL17rc*, *Tnfsf10*, *Tnfsf11*, *Tnfsf14*, and *Tnfsf15* ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}). To validate the transcriptome sequencing results, these DEGs were analyzed by RT-qPCR. Particularly, the relationship between the expression levels of these genes and the severity of infection was given special attention. We found that their expression levels were positively correlated with the severity of infection, with the highest expression in the "Severe" group ([Figure 3](#F3){ref-type="fig"}). These genes can be roughly divided into two families -- interleukin-1 family and TNF superfamily. *Il1a*, *Il18*, and *Il36b* belong to the former gene family. *Tnfsf10*, *Tnfsf11*, *Tnfsf14*, and *Tnfsf15* are the members of the TNF superfamily.

![RT-qPCR analysis on the correlations between the expression of inflammatory/immune response genes and the severity of infection. Healthy: healthy control. Silent: patients without any symptoms. Minor: patients with respiratory tract infection symptoms but without pneumonia. Severe: patients with pneumonia. *N* = 5∼6 per group. ^∗^*p* \< 0.05; ^∗∗^*p* \< 0.01; ^∗∗∗^*p* \< 0.001.](fmicb-10-00130-g003){#F3}

Immunoblotting Validation
-------------------------

Among the above genes, we were interested in the ones that were not reported in adenovirus infection in previous publications. Hence, *Tnfsf10*, *Tnfsf11*, *Tnfsf14*, and *Tnfsf15*, which, respectively, encode TNF-related apoptosis-inducing ligand (TRAIL), receptor activator of nuclear factor kappa-B ligand (RANKL), TNFSF14 (CD258), vascular endothelial growth inhibitor (VEGI), were chosen for the further validation via Immunoblotting. As shown in [Figure 4](#F4){ref-type="fig"}, in the PBMCs of healthy individuals, the protein levels of these molecules were very low. HAdV-55 infection substantially increased the expression of these genes, and their expression levels were positively correlated with the severity of infection, with the highest expression in the "Severe" group. Hence, the Immunoblotting data were consistent with the RT-qPCR results, suggesting that the expression of *Tnfsf10*, *Tnfsf11*, *Tnfsf14*, and *Tnfsf15* indeed reflect the severity of HAdV-55 infection.

![Protein levels of TRAIL, RANKL, TNFSF14, and VEGI in the PBMCs of patients and healthy donors. **(A)** Representative Immunoblotting images. **(B)** Statistics for the protein level of each molecule. The relative expression of each protein was normalized to the GAPDH expression. Healthy: healthy control. Silent: patients without any symptoms. Minor: patients with respiratory tract infection symptoms but without pneumonia. Severe: patients with pneumonia. *N* = 5 per group. ^∗^*p* \< 0.05; ^∗∗∗^*p* \< 0.001.](fmicb-10-00130-g004){#F4}

Discussion
==========

Human adenovirus is a double-stranded DNA virus with a diameter of 70∼90 nm ([@B39]; [@B1]). Although intensive studies had shown the epidemic or clinical properties, the immunological aspect of HAdV infection is rarely discussed. Among multiple HAdV genotypes which belong to seven species, HAdV-55 is a pathogen arising from gene recombination between HAdV-11 and HAdV-14 ([@B61]; [@B66]). According to previous reports, HAdV-55 was more virulent and cause fetal infection. By now, the immunological or inflammatory mechanism of HAdV-55 infection has not been established, and the specific and effective therapies are not available.

Human adenovirus type 55 infection induces complex immune responses, as demonstrated by significantly higher levels of blood IL-17^+^CD4^+^ T lymphocytes and higher levels of serum IFN-γ, IFN-α2, IL-4, and IL-10 ([@B11]). The IL-17^+^ CD4^+^ T lymphocytes, also known as Th17 cells, play an essential role in inflammatory responses and autoimmunity ([@B9]; [@B46]). However, the relationship between the immune responses and pneumonia remains ambiguous. Whether the immune responses, especially the inflammatory reaction, have a profound impact on the severity of HAdV-55 infection is still unclear.

In the current study we analyzed the mRNA profiles of blood leukocytes from HAdV-55-infected patients with distinct infection severity. Interestingly, in comparison with the health control, only a relatively small amount of mRNAs were down-regulated in patients. This might be because that adenovirus-induced innate and adaptive immune responses trigger the activation of a broad spectrum of immune cells including macrophages, granulocytes, dendritic cells, T lymphocytes, and B lymphocytes ([@B14]; [@B16]; [@B32]; [@B2]). The activated immune cells profoundly promote the expression of genes related to proliferation, microbicidal activity and the inflammatory responses. Therefore, perhaps during the reaction of HAdV infection, the primary reaction of immune cells is to express more immunity-or-inflammation-associated proteins, while a tiny fraction of proteins related to immune tolerance or anti-inflammation are transcriptionally down-regulated. This is also why we focused on the up-regulated mRNAs, since these mRNAs reflect the active immune response or inflammation. Through a comprehensive transcriptome sequencing, we identified eight genes of which the expression was significantly up-regulated and positively associated with the infection severity. *Il18*, *Il36b*, *IL17rc*, *Tnfsf10*, *Tnfsf11*, *Tnfsf14*, *Tnfsf15*, and *Il1a* were the up-regulated genes we discovered. Among them, *Il36b* and *Tnfsf15* are newly identified inflammation-related genes in HAdV-55 infection. Our results suggest new gene markers and therapeutic targets for HAdV-55-induced pneumonia.

*Il1a* encodes IL-1α, a cytokine that has already been implicated in the response to adenovirus infection. In response to HAdV-5, macrophage secret IL-1α to trigger IL-1RI-dependent production of pro-inflammatory cytokines and chemokines ([@B19]). The arginine-glycine-aspartic acid (RGD) motifs of HAdV-5 interact with macrophage β~3~ integrins to elicit the IL-1α-mediated response ([@B19]; [@B25]). In addition, IL-1α can facilitate CXCR2-mediated recruitment of neutrophils into the splenic marginal zone during HAdV-5 infection ([@B18]). Thus, IL-1α is a key factor responsible for the activation of pro-inflammatory responses to adenovirus. Interestingly, blockade of IL-1 signaling can improve the toxicity profile of Ad5-based vectors Ad5L and Ad5/35L ([@B50]), suggesting that IL-1α might be associated with the severity of adenovirus infection. Therefore, our data seem consistent with previous research showing that IL-1α is positively correlated with the extent of adenovirus-induced inflammation. However, IL-1α could also be beneficial for the host immune reaction against viral infection, because IL-1R-deficient mice demonstrated an impaired immune response to vaccinia virus infection ([@B56]). In our study, we found that *Il1a* mRNA was positively related to the severity of HAdV-55 infection, suggesting that HAdV-55 triggers macrophages to produce IL-1α. Further investigations are needed to elucidate the role of IL-1α in HAdV-55-induced inflammation especially pneumonia.

*Il-18* is a member of the interleukin-1 family. It encodes IL-18 which contributes to the pathogenesis of autoimmune diseases and inflammation. Previous studies suggest that IL-18 is mainly secreted by monocytes/macrophages in reaction to viral or bacterial stimuli ([@B8]; [@B7]). After stimulation, monocytes/macrophages form inflammasomes in their cytosol and process immature IL-1β and IL-18 into their active mature forms ([@B59]). Mature IL-1β and IL-18 are then secreted out of monocytes/macrophages and bind to their receptors on target cells to activate NF-κB and induce inflammatory mediators such as IFN-γ, adhesion molecules, chemokines and Fas ligand ([@B35]). In this manner, IL-18 is involved in the activation of Th1, Th2, NK cells, IL-17-producing γδ T cells, and macrophages. Our data show that *Il-18* mRNA was highly expressed in severe HAdV-55 infection. It is therefore very likely that HAdV-55 infection induces the transcription of IL-18 in monocytes/macrophages through toll-like receptor (TLR)-related signaling and inflammasome formation, and the expression of IL-18 represents the extent of anti-viral reaction and is closely correlated with the infection severity.

*Il36b* encodes IL-36β (also known as interleukin-1 family member 8), which is another member of the interleukin-1 family. IL-36β is considered to be expressed by monocytes/macrophages, T lymphocytes and B lymphocytes. Nevertheless, the stimuli which induce IL-36β expression remain unclear. It has been reported that other members of IL-36 cytokines such as IL-36α and IL-36γ are secreted by keratinocytes, monocytes, or epithelial cells after stimulation with epidermal growth factor, TLR agonists or inflammatory stimuli ([@B3]; [@B6]; [@B27]; [@B28]). It is likely that IL-36β is produced in a stimulus-dependent manner in inflammatory responses. However, the regulatory mechanisms of the IL-36β expression in different disorders remain to be elucidated. We found that *Il36b* mRNA was closely related to the severity of HAdV-55 infection. To our knowledge, we are the first to report the up-regulation of IL-36β expression in HAdV-55 infection. The target cells of IL-36β are dendritic cells and CD4+ T lymphocytes ([@B27]). It has been reported that IL-36 family members upregulate CD80, CD86, and MHCII and induce the production of IL-12, IL-1β, IL-6, TNF-α, and IL-23 in dendritic cells. Furthermore, IL-36 family members enhance CD4+ T cells to produce IFN-γ, IL-4, and IL-17a ([@B60]). Since IL-36α, IL-36β, and IL-36γ bind to the same receptor complex, it is reasonable to speculate that IL-36β is also involved in the activation of innate and adaptive immune responses in HAdV-55 infection. The exact role of IL-36β in the host defense against HAdV-55 invasion remains unidentified and would be elucidated in further investigations.

*Tnfsf10*, *Tnfsf11*, *Tnfsf14*, and *Tnfsf15* encode TRAIL, RANKL, TNFSF14 (CD258), and VEGI, respectively. TRAIL is a crucial protein secreted by various tissue cells including cells of the immune system such as natural killer (NK) cells, T cells, natural killer T cells (NKT cells), dendritic cells and macrophages ([@B21]). It induces apoptosis of target cells via binding to death receptor 4 and death receptor 5. It has been reported that TRAIL expression is increased in these cells upon activation with different stimuli ([@B23]; [@B37]; [@B62]; [@B20]). Hence, the TRAIL expression level likely reflects the extent of both innate and adaptive immune response, and severe viral infection could elicit robust immune responses and subsequently a high serum TRAIL level. Our findings are consistent with this hypothesis, demonstrating that *Tnfsf10* mRNA was robustly expressed in the PBMCs of patients with severe HAdV-55 infection. Indeed, it has been indicated that TRAIL can act as a biomarker for distinguishing between bacterial and viral infections, since it is consistently up-regulated in virus-infected patients ([@B43]). However, how HAdV-55 infection up-regulates TRAIL expression has not been determined yet. It is also unknown whether HAdV-55 influence TRAIL-mediated apoptosis of virus-infected tissue cells. Previous studies reveal that Ad5-E1A gene product sensitizes cells to TRAIL-dependent killing, whereas E3 gene products, and to a lesser extent E1B-19K, inhibit this effect ([@B47]). Whether HAdV-55 induces similar effects needs to be studied in future.

RANKL is widely expressed in distinct tissues and cells including leukocytes. In particular, it is expressed by T helper cells and it mediates dendritic cell survival and maturation. B cells are another primary source of RANKL in certain conditions ([@B36]; [@B57]). The role of RANKL in anti-viral immunity has been demonstrated in previous research. RANKL is critical for the induction of anti-viral CD8+ effector T cells (CTL) during cutaneous herpes simplex virus infection ([@B24]). RANKL/RANK signaling axis in the protective immune responses in the spleen marginal zone is important for the host response to viral infection and induction of acquired immunity ([@B30]). However, the role of RANKL/RANK signaling in adenovirus infection has not been well studied. Since we found that *Tnfsf11* mRNA was significantly higher in "severe" and "minor" patients, we speculate that in HAdV-55 infection, RANKL is up-regulated in reactive T cells, B cells and macrophages, and the RANKL expression level is positively associated with the infection severity.

Interestingly, TNFSF14 was also closely related to the severity of HAdV-55 infection in our investigation. It is well known that TNFSF14 is expressed on various cell types such as T cells, dendritic cells, macrophages, and NK cells, and LIGHT-induced signaling leads to NF-κB-driven gene activation and inflammatory reactions ([@B49]). Hence, TNFSF14 is a cytokine crucial for the initiation and progression of inflammation. Indeed, increased serum levels of light/tnfsf14 in non-alcoholic fatty liver disease suggests that TNFSF14 potentially promoting hepatic inflammation ([@B42]). Moreover, the herpes virus entry mediator, which is the receptor of TNFSF14, is linked to dysregulated mucosal function such as pneumonia ([@B51]). Given that severe HAdV-55 infection also causes pneumonia, it is likely that TNFSF14 participates in the HAdV-55-induced inflammation in lungs.

To our surprise, VEGI was found to be positively associated with the severity of HAdV-55 infection. VEGI is a cytokine predominantly expressed in endothelial cells and lamina propria (LP) macrophages but not T cells and B cells. It has been paid attention in the tumor study because it inhibits angiogenesis which is critical for tumor growth ([@B45]; [@B64], [@B65]). It is later known that VEGI plays an active role in the modulation of immunity and inflammation. VEGI stimulates T cell activation, Th1 cytokine production, and dendritic cell maturation through death receptor 3 ([@B67]). Additionally, VEGI-mediated signaling favors Th2 cytokine production in the lung, and act as a critical trigger for allergic lung inflammation ([@B22]). Moreover, VEGI also promotes Th17 cell functions ([@B44]). Hence, the increase in VEGI expression in HAdV-55-infected patients probably contributes to the anti-viral response and favors elimination of virus-containing target cells, but might aggravates pneumonia as well. Interestingly, VEGI expression can be stimulated by TNF-α and IL-1 ([@B13]; [@B40]; [@B34]). So it is highly possible that up-regulation of VEGI is a secondary change caused by the initial inflammation after HAdV-55 infection.

Moreover, IL-17RC was also shown to be up-regulated in severe and minor HAdV-55 infection. IL-17RC is a member of the IL-17 receptor family. Other members of this family include IL-17RA, IL-17RB, IL-17RD, and IL-17RE. IL-17RC pairs with IL-17RA to form a heterodimeric receptor which recognizes IL-17A and IL-17F ([@B33]). The IL-17 family cytokines are active players in inflammatory responses and autoimmune reactions ([@B33]). Although the significance of IL-17RC in HAdV-55-induced pneumonia is unidentified, recent studies indicated that the lung epithelium express IL-17RC which promotes respiratory allergy or pulmonary defense against *Klebsiella pneumoniae* ([@B10]; [@B17]). The up-regulation of IL-17RC on the lung epithelium might enhance the inflammatory response in the lung after HAdV-55 invasion, and therefore reflects the extent of pneumonia.

In a recent research, a bioinformatics analysis revealed the close phylogenetic relationship among all HAdV-55 strains. Interestingly, although HAdV-55 strains have high genome identity, the genetic variation such as single-nucleotide non-synonymous substitutions, synonymous substitutions, insertions, and deletion in non-coding regions occurs between different HAdV-55 isolates. In particular, the major non-synonymous substitutions occurs in the protein pVI, which has different functions at various stages of an adenovirus infection ([@B12]). Viral genetic variation is caused by multiple mechanisms such as genetic recombination, gene duplications, gene exchanges and gene adoptions. The most common variation is nucleotide substitution as a result of polymerase error in reading the template in the replication process ([@B48]). Interestingly, no non-synonymous substitutions are present in the major capsid proteins of different HAdV-55 strains ([@B12]), suggesting that the genetic variation might not influence the host immune response to HAdV-55 strains.

Collectively, our research demonstrates the genes that are highly correlated with the severity of HAdV-55 infection. Further studies focusing on those genes will help understand the inflammation mechanism of HAdV-55 infection. Our data might shed light on the pathogenesis of HAdV-triggered pneumonia, and provide new clues for the diagnosis and therapy of HAdV infection.
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